Gap between cardiorenal benefits of SGLT-2 and GLP-1RA is ‘significantly’ narrowing, researchers say

By Editor
19th October 2021
Pharmaceutical, Pharmacy Prescription drugs Research Type 2 diabetes

A new study has identified that SGLT-2 and GLP-1RA are as effective as each other for improving cardiovascular and renal health in people with type 2 diabetes.

The research reports that both GLP-1RA and SGLT-2 inhibitors reduce the risk of major cardiovascular events by up to 12%.

The findings state: “Overall, the result published seem to suggest that the gap between the cardiorenal benefits of SGLT-2 and GLP-1RA is narrowing.”

Previous studies have suggested that SGLT-2 inhibitors are more effective than GLP-1RA for preventing cardiorenal events.

According to prior research, SGLT-2 inhibitors reduce hospital admissions for heart failure three times more than GLP-1RA do.

However, recent analysis has revealed that GLP-1RA is just as beneficial for people with type 2 diabetes who have developed heart failure.

The team of researchers from the University of Campania Luigi said: “GLP-1RA also exerts a significant benefit on heart failure which suggest their use when SGLT-1 inhibitors are contraindicated or not tolerated.”

Individuals with diabetes are 50% more at risk of developing heart or kidney disease compared to those without the condition, the study reports.

To access the entire research analysis, click here.

Comments (0)

Register an account or login to comment